Lidocaine 20mg/2ml (1%) solution for injection ampoules

Negara: Inggris

Bahasa: Inggris

Sumber: MHRA (Medicines & Healthcare Products Regulatory Agency)

Bahan aktif:

Lidocaine hydrochloride

Tersedia dari:

1%) solution for injection ampoules (Advanz Pharma

Kode ATC:

N01BB02

INN (Nama Internasional):

Lidocaine hydrochloride

Dosis:

10mg/1ml

Bentuk farmasi:

Solution for injection

Rute administrasi :

Subcutaneous; Intravenous; Intramuscular

Kelas:

No Controlled Drug Status

Jenis Resep:

Valid as a prescribable product

Ringkasan produk:

BNF: 15020100; GTIN: 5099602354425

Selebaran informasi

READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you. Do not pass it on to
others. It may harm
them, even if their symptoms are the same as yours.
If any of the side effects become serious, or if you notice any side
effects not listed
in this leaflet, please tell your doctor or pharmacist.
The product is referred as above but for ease it has been mentioned as
Lidocaine
hydrochloride throughout the leaflet.
In this leaflet:
1. What Lidocaine Hydrochloride is and what it is used for
2. Before you are given Lidocaine Hydrochloride
3. How Lidocaine Hydrochloride is given to you
4. Possible side effects
5. How to store Lidocaine Hydrochloride
6.Further information
1. WHAT LIDOCAINE HYDROCHLORIDE IS AND WHAT IT IS USED FOR
Lidocaine Hydrochloride is a local anaesthetic and belongs to a class
of drugs called amide
type local anaesthetics. It produces loss of feeling or sensation
confined to one part of the body.
Lidocaine Hydrochloride Injection may be used to produce local
numbness (anaesthesia)
by injection of the solution into or around the area of operation. It
may also be used to
produce local anaesthesia by injection of the solution close to the
nerves whose conduction
is to be cut off, or into the epidural space near the spinal cord, or
by administering the
solution into a vein in a limb that has been isolated from the
circulation by means of a
tourniquet (bandage that stops the flow of blood from vessel by
applying pressure).
2. BEFORE YOU ARE GIVEN LIDOCAINE HYDROCHLORIDE
YOU SHOULD NOT BE GIVEN THIS MEDICINE:
• if you know you are allergic to lidocaine hydrochloride, to any of
the other ingredients
(see Section 6 of this leaflet) or to other similar amide type
anaesthetics
• if you suffer from state of decreased blood volume (hypovolaemia)
• if you suffer from abnormality of impulse propagation in the heart
causing decreased
bloo

Karakteristik produk

OBJECT 1
LIDOCAINE HYDROCHLORIDE INJECTION B.P. 1.0% W/V
Summary of Product Characteristics Updated 18-Sep-2014 | Concordia
International - formerly AMCo
1. Name of the medicinal product
Lidocaine Hydrochloride 1% w/v Solution for Injection
2. Qualitative and quantitative composition
Each 1ml of solution contains 1.0% w/v of Lidocaine Hydrochloride B.P.
3. Pharmaceutical form
Solution for Injection
4. Clinical particulars
4.1 Therapeutic indications
Lidocaine is a local anaesthetic of the amide group. The injectable
form has a wide range of applications
for nerve blockade. It can be used by percutaneous infiltration; to
block a major nerve plexus such as the
brachial; for epidural anaesthesia; for intravenous regional
analgesia.
4.2 Posology and method of administration
The dosage should be adjusted according to the response of the patient
and the site of administration. The
lowest concentration and smallest dose producing the required effect
should be given. The maximum dose
for healthy adults should not exceed 200mg.
Children and elderly or debilitated patients require smaller doses,
commensurate with age and physical
status.
4.3 Contraindications
Known hypersensitivity to anaesthetics of the amide type.
Complete heart block
Hypovolaemia
4.4 Special warnings and precautions for use
Lidocaine should be administered by persons with resuscitative skills
and equipment. Facilities for
resuscitation should be available when administering local
anaesthetics.
It should be used with caution in patients with myasthenia gravis,
epilepsy, congestive heart failure,
bradycardia or respiratory depression, including where agents are
known to interact with Lidocaine either
to increase its availability or additive effects e.g. phenytoin or
prolong its elimination e.g. hepatic or end
renal insufficiency where the metabolites of Lidocaine may accumulate.
Intramuscular Lidocaine may increase creatinine phosphokinase
concentrations which can interfere with
the diagnosis of acute myocardial infarction. Lidocaine has been shown
to be